Biblio
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
[Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(6):1910-1915.
. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Front Immunol. 2023;14:1269163.
. .